Abstract
This study reviewed 56 patients with significant metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa infections between May 2002 and March 2004 to identify features associated with mortality. Immunosuppression (p 0.002), bacteraemia (p 0.08) and inadequate antimicrobial therapy (p <0.001) were associated with death. Among those patients treated with adequate therapy, the use of multiple drug treatment regimens (two or three active agents) was associated with a non-significant two-fold increase in survival (p 0.45). Further prospective studies are warranted to determine the optimal treatment of MBL-producing P. aeruginosa infections.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Anti-Bacterial Agents / therapeutic use
-
Aztreonam / therapeutic use
-
Canada / epidemiology
-
Catchment Area, Health*
-
Colistin / therapeutic use
-
Cross Infection / epidemiology
-
Female
-
Humans
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas Infections / epidemiology
-
Pseudomonas Infections / mortality
-
Pseudomonas aeruginosa / drug effects*
-
Pseudomonas aeruginosa / isolation & purification
-
Pseudomonas aeruginosa / metabolism*
-
Retrospective Studies
-
Survival Rate
-
beta-Lactamases / biosynthesis*
Substances
-
Anti-Bacterial Agents
-
beta-Lactamases
-
Aztreonam
-
Colistin